A person chasing the broader insulin-sensitivity/stress-signaling mechanism, injectable, with the endogenous-origin asterisk, lands on MOTS-c
Antioxidant capacity of follicular fluid from patients undergoing in vitro fertilization
It is not a medicine, supplement, food, cosmetic, medical device, diagnostic product or treatment product
HGF/c-Met signaling is a well-established oncogenic pathway: c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular) HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use